Launch One Acquisition Corp.

This amendment fundamentally resets the SPAC’s survival timeline and activates an immediate liquidity option for investors who reject prolonged capital deployment risk. According to the Board, each executed Election drains proportional Trust Account capital, which management acknowledges could leave insufficient liquidity to satisfy potential target closing conditions, thereby elevating reliance on the $1,000,000 sponsor working capital facility or alternative financing. The sponsor’s pledge of 2,932,500 founder shares to secure the credit agreement introduces direct collateral risk to insider equity if the Company liquidates without a merger. The Board also warns that mass redemptions triggered by this amendment could reduce public holder counts below Nasdaq’s generally required 400-public-holder threshold, potentially triggering delisting procedures that would restrict secondary market liquidity and impose penny stock trading regulations. The Board unanimously recommends approval, and with the Sponsor’s committed 20.0% voting block controlling the Founder Shares, the critical two-thirds supermajority threshold for Cayman Islands special resolutions becomes structurally manageable, though final outcomes remain strictly contingent on independent public shareholder Elections. Auditor fees of approximately $116,895 for fiscal year 2025 and $128,440 for the period from inception through December 31, 2024 were paid to WithumSmith+Brown, PC, whom the Audit Committee nominated for ratification. Director and officer groups (Ryan Gilbert, Chris Ehrlich, Jurgen van de Vyver, Brian Atwood, Rodney A. Ferguson, and Risa Stack) disclaim individual beneficial ownership of the 5,750,000 founder shares held by the Sponsor. All projections regarding Potential Business Combinations, regulatory CFIUS review risks, PFIC tax implications, Nasdaq compliance thresholds, and sponsor lending economics are attributed exclusively to Launch One Acquisition Corp.’s Board of Directors, executive management, the Audit Committee, or the Sponsor as formally disclosed in this filing.

This PRE 14A forces an immediate liquidity and timeline bifurcation for public shareholders without the anchor of an announced merger. Because the board explicitly confirms there is no target, the extension operates strictly as administrative runway rather than deal-execution progress. Investors face a dual redemption architecture—immediate Election and future business combination votes—which the board cautions could create a liquidity vacuum that starves prospective acquirers of required cash. The Sponsor’s economic exposure is fully transparent: founder shares and private warrants carry zero liquidation value if the company winds up by July 15, 2026, while the Sponsor has leveraged over half its founder equity to secure external debt expressly to fund extension-period overhead. The $15,000 proxy solicitation expenditure and permitted insider open-market share purchases signal active capital allocation to secure the required two-thirds Cayman Islands threshold. Calendar trackers will adjust the absolute liquidation floor to January 15, 2027, subject to monthly renewals, though the board flags Nasdaq delisting risk if post-redemption public holder concentrations drop below 400. Additionally, the filing supplies detailed PFIC tax guidance, advising U.S. Holders that IRS treatment of redemption proceeds as distributions may strip preferential capital gains rates due to passive asset classification, triggering default PFIC taxation with ordinary income allocation and interest penalties on deferred gains.

The termination of the Minovia deal leaves LPAA without a business combination target less than four months before the July 15, 2026 deadline, raising the risk of liquidation. The new secured working capital loan and pledge of founder shares indicate the Sponsor is financially supporting the search but also creating potential control risks if defaults occur. The trust value per share of $10.77 still provides a modest floor for public shareholders.

The trust value per share is $10.67, below the $10.86 assumed by the user, and the liquidation deadline is July 15, 2026, not January 15, 2027. The termination of the Minovia deal resets the search to zero with less than four months left before forced liquidation. The sponsor's pledge of majority founder shares to secure working capital indicates financial stress and potential control implications if an extension or deal is not achieved. The going concern warning and low cash reserves heighten the risk of no deal and a forced redemption at approximately $10.67 per share, less any expenses.

This transaction directly modifies extension mechanics and sponsor risk profiles. Management cited the company's 'limited cash balance at year end' as the rationale for securing additional working capital, effectively using sponsored debt to fund ongoing operations and avoid forced liquidation votes, thereby keeping the redemption calendar intact. However, by borrowing $1,000,000 from external lenders and encumbering over half of its founder equity, the sponsor has tied its own financial exposure to achieving a deal or successfully extending the deadline. The Credit Agreement creates hard deadlines, defining events of default if the company fails to file an extension proxy or execute a definitive merger agreement by specified dates, which intensifies schedule pressure on management. Cost structures embedded in the note include a $25,000 expense withholding on the initial draw and caps of $20,000 per occurrence for refinancing or enforcement costs, reducing net capital available for targets or general overhead. Standard security parameters noted in the cover page confirm warrants maintain a $11.50 exercise price. Crucially, the trust waiver ensures that neither corporate liabilities nor the sponsor's third-party creditors can access IPO trust proceeds, insulating public redemption values from this financing maneuver while highlighting increased reliance on sponsor-funded bridge capital ahead of a transaction.

The Registrant’s board of directors and management stated the financing addresses limited year-end cash balances to cover operational expenses and prior business combination efforts. However, the note records a 20% original issue discount, setting the maximum face principal at $1,250,000 against $1,000,000 in actual draws, accruing 8% annual interest with an 18% default adder totaling 26%, and imposing a 10% prepayment penalty. On the issuance date, the Company agreed to withhold up to $25,000 from the initial tranche to reimburse the Sponsor’s funding costs, with additional out-of-pocket reimbursements for refinancing or enforcement capped at $20,000 per occurrence. Because lender recourse is strictly limited to the pledged founder shares and the debt matures upon business combination consummation or liquidation, the Sponsor bears the direct economic risk of failure without jeopardizing public shareholder trust assets. For investors tracking the redemption calendar and extension timeline, the explicit conditioning of the two $250,000 drawdowns on a shareholder extension vote confirms that operational runway remains tied to continued approval, while the steep implicit borrowing costs and expense offsets will further reduce net capital available for transaction pursuit.

The execution of this release legally extinguishes the proposed transaction, removing merger-related equity dilution, management compensation triggers, and target-specific valuation assumptions from the capital structure. By preserving the trust waiver provision, the filing ensures that shareholder redemption rights and principal protection mechanisms remain fully enforceable if the SPAC liquidates during its remaining search period. Investors tracking the calendar should prepare for the sponsor’s next procedural step—either a targeted acquisition announcement, a proxy solicitation for a trust extension, or a definitive agreement with a different counterpart—as the clean discharge of liabilities and automatic termination of lock-ups eliminate prior contractual frictions. The document contains no forward-looking financial projections, customer concentration data, product pipeline metrics, or litigation disclosures, focusing exclusively on the structural unwind and the sponsor’s ongoing mandate to identify a replacement business combination.

The Termination and Release Agreement definitively halts the Minovia Therapeutics merger pathway, meaning no shareholder approval vote, tender offer, or redemption event tied to that specific combination will occur. Public shareholders retain their outstanding Class A ordinary shares ($0.0001 par value) and Warrants (exercisable at $11.50 per share) without a deal-triggered liquidity event. Because the SPAC remains in SEARCHING status with a hard deadline of January 15, 2027, the sponsor must now identify and negotiate a replacement target within the remaining contractually defined window to avoid potential liquidation and trust distribution procedures. The exhaustive mutual release and indefinite covenant not to sue permanently eliminates bilateral litigation exposure regarding the aborted transaction, while the preserved trust waiver provision maintains original shareholder protections against post-termination creditor or counterparty claims. Beyond deal mechanics, the filing confirms the intended acquisition target structure: Minovia Therapeutics Ltd. (an Israeli company limited by shares) merging into Mito US One Ltd. (Pubco) via Mito Sub Israel Ltd., with cancellation provisions outlined for outstanding In-the-Money Company Options, Company SAFEs, and other Convertible Securities. The agreement is governed by Delaware law, subjects disputes exclusively to the Chancery Court of the State of Delaware, includes a binding jury trial waiver, and was executed by Chief Executive Officer Chris Ehrlich for the SPAC, Chief Financial Officer Jurgen van de Vyver for the Sponsor, and Natalie Yivgi-Ohana for Minovia, Pubco, and the Seller Representative.

For investors tracking redemption windows and deal sequencing, this Form 425 signals that the formal SEC review and shareholder solicitation phases are still preliminary, as the Form F-4 remains unfiled and unapproved. The absence of a filed proxy statement means no binding redemption terms, supplemental plan of distribution, or definitive purchase price adjustments are active, leaving the January 15, 2027 deadline structurally intact but operationally dormant for this specific transaction path. The disclosed patent grants and MNV-201 clinical data are intended to fortify the merger thesis ahead of the eventual definitive proxy mailing. Once the F-4 is declared effective, redemption calendars will become actionable, and investors will receive exact trust reconstruction mechanics, sponsor equity lock-up details, and audited pro forma financials; until then, this filing serves as a preliminary validation of asset viability rather than a binding transaction update.

This is the first quarterly report since the Minovia deal was signed; it shows the trust is growing from interest, but the company is burning cash and faces a tight timeline to close by December 24, 2025 (under the BCA) or July 15, 2026 (under its charter). Investors need to monitor progress on the bridge financing (at least $5 million required) and the $23 million minimum cash condition. The going concern disclosure indicates risk of liquidation if the deal fails.

For LPAA investors tracking redemption mechanics and deal execution, this Rule 425 communication validates that the target is advancing R&D pipeline funding ahead of the merger and reiterates the 'late 2025' closing horizon. However, because the definitive proxy/prospectus (Form F-4) remains unfiled and uneffective, the official document that will set precise redemption windows, pro forma trust distribution mechanics, and voting thresholds has not yet been locked. Until the Registration Statement is filed and declared effective, shareholders lack finalized terms on conversion ratios or mandatory vote requirements. The grant announcement and clinical sample collection targets serve as operational validation for Minovia’s valuation narrative but do not independently alter SPAC trust accounting, sponsor conduct obligations, or the existing trust/share balance and January 15, 2027 deadline.

The filing confirms that Launch One has a signed deal with Minovia Therapeutics Ltd. (Israeli biotech), providing a concrete path to closing by December 24, 2025 (the outside termination date). The trust is healthy at $10.46/share with $240.6M. However, the company discloses substantial doubt about its ability to continue as a going concern due to limited working capital ($263,740 cash, $183,171 surplus) and the liquidation deadline. The Minovia deal includes a $23M minimum cash condition and requires at least $5M bridge financing (deadline extended to ~60 days after signing). Shareholders should watch for the F-4 registration statement and shareholder vote.

The communication functions as permissible solicitation material ahead of the F-4, providing clinical milestones intended to shape shareholder voting and redemption calculus. Co-founder and CEO Natalie Yivgi-Ohana stated the Phase 2 trial met its primary safety endpoint, reporting zero treatment-related severe adverse events and no anti-mitochondrial antibodies. Chief Scientific Officer Noa Sher reported all adverse events were transient, with most resolving within four days, and attributed the majority to the pre-administration apheresis procedure required to procure cells. The Company states that at a six-month follow-up, two of the first three patients experienced improved height standard deviation scores relative to pre-treatment baselines, with quality of life scores likewise improving for those two patients; this efficacy signal relies on a novel endpoint identified through a Children’s Hospital of Philadelphia natural history study supported by Minovia funding. Enrollment continues with trial completion expected before the end of 2025. Additional data from two compassionate-use Kearns-Sayre syndrome patients also showed favorable safety and improved quality of life. The FDA granted Fast Track and Rare Pediatric Disease Designations; the Company expects to initiate registrational studies in 2026 and notes historic pediatric priority review vouchers commanded prices exceeding US$100 million, though voucher programs are currently paused awaiting Congressional reauthorization. The filing’s forward-looking risk section explicitly warns of potential Business Combination Agreement termination, financing shortfalls, regulatory delays, stock exchange listing failures, and the risk that estimated shareholder redemptions, purchase price adjustments, or cash-position constraints could materially disrupt projected economic outcomes.

This filing moves LPAA from 'SEARCHING' to a definitive deal with a specific target, valuation, and timeline. It establishes a minimum cash condition of $23 million, meaning the deal can fail if too many public shareholders redeem or if Transaction Financing falls short. The requirement for at least $5 million in Bridge Financing within 30 days is a near-term risk of termination. The sponsor's earnout shares are aligned with the target's milestones, but the absence of a termination fee and the existence of a patent-based termination right (FTO Opinion) are unusual and provide avenues for either party to walk away. The 1-year lock-up for company insiders is standard. The trust per-share value of $10.86 provides a significant premium to the $11.50 earnout threshold.

This is the fundamental event for a SPAC in SEARCHING status: it now has a target. The trust value is high ($10.86/share), creating a large potential redemption overhang. The $23 million minimum cash condition is a critical threshold for viability post-close and depends heavily on redemptions and the ability to raise $23M+ in new PIPE/backstop financing. The earnout structure (shares tied to $11.50 stock price or Phase 3 trial start) provides a long-duration incentive. The 2025-12-24 outside date creates a hard deadline. The lack of post-closing indemnification for the target's reps is a notable risk factor for public shareholders.

The publication materially advances the deal’s execution timeline relative to LPAA’s January 15, 2027 search deadline, while positioning a pending Form F-4 filing that will deliver exact redemption mechanics, pro forma trust valuation, and proxy materials. According to Minovia Co-founder and CEO Natalie Yivgi-Ohana, Ph.D., the FDA’s grant of Fast Track and Rare Pediatric Disease Designations for the Phase 2 MNV-201 trial in Pearson Syndrome validates the clinical approach and could decrease time-to-market. The document further notes that a pediatric priority review voucher associated with the designation has historically commanded prices in excess of US$100 million, though the program remains on hold awaiting congressional reauthorization. Minovia states plans to finalize pivotal trial designs and initiate registrational studies in 2026, operates a GMP manufacturing facility in Haifa, Israel, is expanding to the U.S., tests MNV-201 for Myelodysplastic Syndrome alongside Pearson Syndrome, and maintains John Cox as chair of its board. For investors tracking redemption behavior, the forthcoming proxy distribution represents the critical inflection point where trust value, redemption windows, and sponsor conduct terms become contractually binding, making this communication a structural prerequisite to actionable voting decisions rather than a standalone term revision.

This 8-K initiates the proxy solicitation and Form F-4 registration process, dictating the mechanics for shareholder redemptions and votes against the January 15, 2027 deadline. The transaction structure conditions available trust proceeds of approximately $239.7 million, alongside a mandatory bridge financing of at least $5 million and anticipated PIPE of at least $18 million, on satisfying customary closing conditions to fund pipeline milestones. In the press release and presentation, sponsors characterize the addressable opportunity as a '$1 trillion+' longevity and regenerative medicine market, noting their advisory group has successfully completed eight prior SPAC mergers. Minovia Co-Founder and CEO Natalie Yivgi-Ohana asserts the MAT platform delivers multi-system benefits and durable safety across 23 treated patients, while stating total capital raised to date stands at '~$50 million,' inclusive of '~$33 million in equity' and '$20 million in non-dilutive strategic R&D collaboration with Astellas Pharma.' Launch One CEO Chris Ehrlich adds that U.S.-based GMP manufacturing is scheduled for end-of-2025 readiness.

According to the press release authored by Launch One CEO Chris Ehrlich and Minovia Co-Founder and CEO Natalie Yivgi-Ohana, the transaction positions the combined company to advance lead product MNV-201 through a Phase 2 trial for Pearson Syndrome and a Phase 1b study for low-risk Myelodysplastic Syndrome, citing awarded FDA Fast Track and Rare Pediatric Disease designations. The presentation, prepared jointly by the parties, attributes preclinical efficacy claims—including reversed aging phenotypes in aged mouse kidneys, improved locomotor function, and stabilized renal and hematologic markers in humans—to internal studies and third-party literature, noting that Minovia’s management reports 23 patients have been treated to date with no documented drug-product related adverse events. Leadership claims a regulatory-aligned pathway to launch MAT-based longevity offerings through global clinic partnerships in 2026 using a recurring revenue-share model, while disclosing a cumulative historical capital raise of approximately $50 million (broken down as roughly $33 million in private equity and $20 million in non-dilutive R&D collaboration with Astellas Pharma). The filing does not modify the existing trust balance or extension rules but supplies the critical valuation parameters, redemption pricing formula, and expected capital deployment schedule ($25 million targeted over 24 months) that determine whether public shareholders receive their pro rata trust portion or participate in the combined company’s equity upside.

This 8.6% block establishes a fixed voting cohort for any future proposed business combination, directly setting the baseline shareholder participation required before redemption rights trigger or target approval fails. The explicit ordinary-course certification lowers near-term governance volatility and signals the LMR entities will not force extension negotiations or sponsor removal absent a transaction announcement. The warrant structure introduces 990,000 contingent shares carrying an $11.50 strike, which sits above the stated $10.86 trust benchmark, meaning warrant exercise would only be economically rational post-combination if the merged entity trades above $11.50 before the five-year expiry. No claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel adjustments appear in the filing beyond the ownership and control attestations.

The filing contains no updates to LPAA's redemption schedule, trust value per share, January 15, 2027 termination deadline, extension mechanics, business combination progress, or sponsor governance. Because the reporters expressly disclaimed control-seeking purpose, the filing does not alter the SPAC's immediate liquidity timeline or force shareholder action. Nevertheless, an 8.8% institutional block establishes a concentrated shareholder base that will factor into any future proxy solicitations, amendment votes, or merger negotiations, requiring continued tracking should LPAA advance toward a target announcement or seek a trust extension.

The filing provides updated trust value and per-share redemption amount ($10.12), confirms no deal progress, and reiterates the 24-month deadline from IPO (July 15, 2024). Investors monitoring redemption value should note trust per share has grown from $10.00 at IPO due to interest and unrealized gains. The lack of target discussions and going concern warning indicate timeline pressure. Sponsor conduct appears standard; no red flags.

This routine listing mechanism increases marketability and price discovery for the equity and warrant components without diluting the trust pool, altering the redemption calendar, or triggering a mandatory vote. Per the press release authored by the registrant and signed by Chief Executive Officer Chris Ehrlich on August 29, 2024, the Company’s stated investment strategy targets healthcare and healthcare-related industries, specifically life sciences on a global basis, seeking acquisitions of established businesses of scale. The filing lists Jurgen van de Vyver as the designated corporate contact at (510) 692-9600 and anchors the principal executive offices at 180 Grand Avenue, Suite 1530, Oakland, CA 94612. There is no disclosure regarding pending litigation, operating revenue, customer concentration, technological roadmaps, strategic partnerships, or changes to sponsor fiduciary conduct.

First post-IPO financial report confirming trust value ($10.00/share), 24-month deadline (July 15, 2026), and no deal progress. Redemption mechanics per standard SPAC terms. Sponsor loans repaid. Administrative services agreement in place.

The report confirms the exact trust balance and structural mechanics that will govern shareholder redemption calculations and liquidation payouts, cementing a hard 24-month execution deadline without invoking any extension provisions. By publicly committing no pre-IPO target negotiations, the company resets deal-progress timelines for investors tracking conversion windows. The documentation of sponsor-purchased private warrants, locked-up founder shares, and ongoing $12,500 monthly administrative fees provides transparency into alignment incentives and ongoing cash burn outside the trust. Disclosure of the $10,950,000 deferred underwriting fee clarifies a major contingent liability payable only upon business combination completion. Together, these elements establish the financial baseline and operational constraints before public trading and target acquisition begin.

What changed: A Form 8-K Current Report and accompanying DEFA14A Definitive Additional Materials filed by Launch One Acquisition Corp. to formally announce the postponement of a shareholder meeting and to update the calendar for exercising redemption rights in connection with a proposed amendment to extend the company's business combination timeline. Launch One Acquisition Corp. has rescheduled its extraordinary general meeting from Tuesday, July 7, 2026, to Friday, July 10, 2026. In direct response, the Company has pushed the redemption exercise deadline to Wednesday, July 8, 2026, at 5:00 p.m., Eastern Time. The substantive proposal remains identical: shareholders are being asked to approve amendments to the memorandum and articles of association that would extend the deadline to consummate an initial business combination from July 15, 2026, to January 15, 2027. The meeting location remains the offices of Ellenoff Grossman & Schole LLP in New York, and the record date stays fixed at May 15, 2026. Why it matters: This filing directly reindexes the redemption and proxy voting schedule ahead of the original July 15, 2026, liquidation trigger. Shareholders now have until July 8, 2026, to submit redemption requests before the rescheduled July 10, 2026, vote on the six-month extension proceeds. The postponement does not introduce new claims regarding customers, revenue, market size, technology, partnerships, litigation, or sponsor conduct. As executed by Chief Executive Officer Chris Ehrlich, the communication contains no offer or solicitation beyond the proxy materials already distributed beginning on or about June 12, 2026. Investors must monitor the shifted July 8, 2026, redemption cutoff closely, as failure to act by that precise time may force cash retention or trigger conversion mechanics if the extension vote ultimately fails.

What changed: Definitive Proxy Statement convened by Launch One Acquisition Corp. to solicit shareholder votes at an Extraordinary General Meeting in lieu of an Annual General Meeting. The filing proposes amending the Company’s Articles to extend the deadline to consummate an initial business combination from July 15, 2026, to January 15, 2027. It activates a shareholder redemption election exercisable prior to 5:00 p.m. Eastern Time on July 2, 2026, priced at approximately $10.83 per share based on a reported Trust Account balance of approximately $249,132,955 as of June 2, 2026. The document confirms a Working Capital Promissory Note executed on March 20, 2026, authorizing the Sponsor to lend up to $1,000,000 across three tranches, secured by a pledge of 2,932,500 founder shares to Keystone Capital Partners, LLC. The Sponsor states it intends to vote all 5,750,000 founder shares in favor of the extension and related proposals. Why it matters: According to the proxy statement, the Board concludes that there may not be sufficient time before July 15, 2026, to conduct a separate shareholder vote for a Potential Business Combination and consummate a closing without this extension. Shareholders face a direct liquidity decision: tender shares for redemption at the calculated pro rata trust value before the July 2, 2026 deadline, or retain exposure to a search period where the company discloses having no definitive agreement with a target entity. The filing warns that large-scale redemptions could deplete trust cash below thresholds required for business combination closing conditions or trigger Nasdaq delisting proceedings, as the exchange generally requires a minimum of 400 public holders. Management also discloses that 6,000,000 private placement warrants were previously issued to Sponsor and Cantor Fitzgerald & Co. at $1.00 each, totaling $6,000,000 in gross IPO-side proceeds, with an exercise price of $11.50 per share that remains unexercised until after a business combination. The working capital facility carries an 8% annual interest rate, a 20% original issue discount, and defaults interest at an additional 18%, with repayment dependent on successful deal execution. Furthermore, the filing notes audit fees of $116,895 for the year ended December 31, 2025 and $128,440 for the inception period through December 31, 2024, paid to WithumSmith+Brown, PC, whose appointment the Board recommends ratifying. The Board attributes all extension recommendations to fiduciary assessments that continuing the search period serves shareholder interests by preserving optionality for a Potential Business Combination valuation event.

What changed: Revised Preliminary Proxy Statement (PRER14A) for Launch One Acquisition Corp. convening an Extraordinary General Meeting in lieu of an Annual General Meeting to solicit shareholder votes on a business combination deadline extension, auditor ratification, and adjournment authority. The Board proposes amending the Amended and Restated Memorandum and Articles of Association to extend the deadline to consummate an initial business combination from July 15, 2026, to January 15, 2027. According to the Board, public shareholders may exercise an 'Election' to redeem Class A ordinary shares immediately upon the extension’s effectiveness at a per-share price calculated using the exact aggregate Trust Account deposits and interest, divided by then-issued public shares. The Board states that if the Extension passes but no deal closes by the Extended Date, operations will cease, public shares will be redeemed from remaining Trust funds, and all warrants will expire worthless. Sponsor Launch One Sponsor LLC controls 5,750,000 founder shares (20.0% of outstanding shares) and discloses its intent to vote 'FOR' all proposals. The Board details a Working Capital Promissory Note enabling Sponsor to lend up to $1,000,000 in three tranches consisting of an initial $500,000 and two subsequent $250,000 installments, carrying a 20% original issue discount, 8% annual interest, a 26% default interest rate, and a 10% prepayment penalty (subject to consent). To secure related lender obligations, Sponsor pledges 2,932,500 Class B ordinary shares (approximately 51% of its founder stake) to Keystone Capital Partners, LLC as agent, with the filing noting the loans are non-recourse to Sponsor and lender recourse is limited to the pledged collateral. Okapi Partners LLC receives a fixed $15,000 fee plus expense reimbursement for proxy solicitation. The filing leaves specific Trust Account balances and precise meeting/redemption deadlines as placeholders ('$ ', '[ ● ]') due to its preliminary status. On-screen data confirms the SPAC completed its IPO on July 15, 2024, generating $230,000,000 in gross proceeds and selling 6,000,000 private placement warrants at $1.00 each to Sponsor and Cantor Fitzgerald & Co. Why it matters: This amendment fundamentally resets the SPAC’s survival timeline and activates an immediate liquidity option for investors who reject prolonged capital deployment risk. According to the Board, each executed Election drains proportional Trust Account capital, which management acknowledges could leave insufficient liquidity to satisfy potential target closing conditions, thereby elevating reliance on the $1,000,000 sponsor working capital facility or alternative financing. The sponsor’s pledge of 2,932,500 founder shares to secure the credit agreement introduces direct collateral risk to insider equity if the Company liquidates without a merger. The Board also warns that mass redemptions triggered by this amendment could reduce public holder counts below Nasdaq’s generally required 400-public-holder threshold, potentially triggering delisting procedures that would restrict secondary market liquidity and impose penny stock trading regulations. The Board unanimously recommends approval, and with the Sponsor’s committed 20.0% voting block controlling the Founder Shares, the critical two-thirds supermajority threshold for Cayman Islands special resolutions becomes structurally manageable, though final outcomes remain strictly contingent on independent public shareholder Elections. Auditor fees of approximately $116,895 for fiscal year 2025 and $128,440 for the period from inception through December 31, 2024 were paid to WithumSmith+Brown, PC, whom the Audit Committee nominated for ratification. Director and officer groups (Ryan Gilbert, Chris Ehrlich, Jurgen van de Vyver, Brian Atwood, Rodney A. Ferguson, and Risa Stack) disclaim individual beneficial ownership of the 5,750,000 founder shares held by the Sponsor. All projections regarding Potential Business Combinations, regulatory CFIUS review risks, PFIC tax implications, Nasdaq compliance thresholds, and sponsor lending economics are attributed exclusively to Launch One Acquisition Corp.’s Board of Directors, executive management, the Audit Committee, or the Sponsor as formally disclosed in this filing.

What changed: An SEC Form 8-K (Item 5.02) reporting the resignation of Director and Audit Committee Chair Dr. Risa Stack and the appointment of Director Daniel Clifford Rogers as her replacement and new Audit Committee Chair. Effective June 2, 2026, Dr. Risa Stack stepped down from the board and all committee roles. The board immediately appointed Daniel Clifford Rogers, age 56, to fill the vacancy and named him chair of the audit committee. As part of his appointment, Mr. Rogers executed joinders to the company's existing Letter Agreement (dated July 11, 2024) and Registration Rights Agreement (dated July 11, 2024). Per the Letter Agreement, he committed to waiving certain redemption rights and voting any ordinary shares he holds in favor of an initial business combination. The filing explicitly states that Dr. Stack's departure was not caused by any disagreement with the company regarding its operations, policies, or practices. Mr. Rogers also entered into a standard director indemnity agreement. Why it matters: This filing expands the pool of insiders bound by the July 11, 2024 Letter Agreement, adding another guaranteed vote in favor of a future business combination and locking in additional shares against early redemption at closing. The appointment introduces a director with specialized experience in the fintech and SaaS sectors (former CFO of Newcourt Acquisition Corp., Papaya Growth, and Helpshift; former CEO/Founder of FintechForce), which may align with the SPAC's target industry search. There are no updates to the capital structure, the per-share trust value remains cited at $10.86, and the redemption/extenuation deadline remains firmly set for January 15, 2027. The clean break noted with the departing director suggests no current friction between management and the board, supporting continued operational progress toward a deal before the deadline.

What changed: A Form 3 initial statement of beneficial ownership filing for Launch One Acquisition Corp. Per the SEC submission, director Daniel C. Rogers reported no non-derivative transactions or holdings. The document contains no references to redemption deadlines, trust value mechanics, extension provisions, target acquisition progress, or sponsor behavior. Why it matters: As a routine administrative disclosure, the filing does not adjust the company’s redemption calendar, modify trust account protections, or signal movement toward a business combination. Because the filing text explicitly states no insider positions changed, there is no immediate indication of altered sponsorship alignment or director confidence relative to public shareholders. Investors seeking developments on financing commitments, target due diligence timelines, or potential extension votes should await subsequent proxy statements, Form 8-K operational updates, or recorded earnings calls.

What changed: Preliminary Proxy Statement (Form PRE 14A) convening an Extraordinary General Meeting to solicit shareholder votes on a corporate charter extension and meeting adjournment proposal. The filing advances a proposal to amend the Articles to push the business combination deadline from July 15, 2026 to January 15, 2027, permitting monthly extensions up to [ ● ] times until [ ● ]. The board states it lacks a definitive agreement for a Potential Business Combination and believes insufficient time remains before the original July 15, 2026 cutoff to secure shareholder approval for a transaction. Accordingly, the filing establishes a concurrent Election allowing public shareholders to redeem shares for a per-share cash price calculated as the aggregate Trust Account balance divided by public shares then in issue, with physical or DWAC tenders required prior to 5:00 p.m. Eastern Time on [ ● ], 2026. On the May 15, 2026 record date, the company had 28,750,000 ordinary shares outstanding, comprising 23,000,000 public shares and 5,750,000 founder shares. The board states approval demands a special resolution of at least two-thirds of voting shares present. The Sponsor, Launch One Sponsor LLC, holds all 5,750,000 founder shares (20.0% of total) and intends to vote FOR the proposals. The Sponsor has pledged 2,932,500 founder shares to Keystone Capital Partners, LLC as collateral under a Credit Agreement financing up to $1,000,000 in loans to the Company ($500,000 initial tranche, two subsequent $250,000 tranches). The Company states it hired Okapi Partners LLC for proxy solicitation at a flat fee of $15,000 plus reimbursable expenses. The filing warns that substantial Election redemptions could drain the Trust Account, potentially causing future deals to fail unless acquirers waive closing conditions. Should the extension fail, dissolution proceedings would begin within 10 business days, with up to $100,000 of interest deductible for wind-down costs. The board notes that six million private placement warrants, originally sold at $1.00 apiece to the Sponsor and Cantor Fitzgerald & Co. for $6,000,000 gross proceeds, will expire worthless upon liquidation, as they carry a $11.50 exercise price. The July 15, 2024 IPO placed $230,000,000 in gross proceeds into the Trust Account, currently invested in Treasury bills maturing in 185 days or less. Why it matters: This PRE 14A forces an immediate liquidity and timeline bifurcation for public shareholders without the anchor of an announced merger. Because the board explicitly confirms there is no target, the extension operates strictly as administrative runway rather than deal-execution progress. Investors face a dual redemption architecture—immediate Election and future business combination votes—which the board cautions could create a liquidity vacuum that starves prospective acquirers of required cash. The Sponsor’s economic exposure is fully transparent: founder shares and private warrants carry zero liquidation value if the company winds up by July 15, 2026, while the Sponsor has leveraged over half its founder equity to secure external debt expressly to fund extension-period overhead. The $15,000 proxy solicitation expenditure and permitted insider open-market share purchases signal active capital allocation to secure the required two-thirds Cayman Islands threshold. Calendar trackers will adjust the absolute liquidation floor to January 15, 2027, subject to monthly renewals, though the board flags Nasdaq delisting risk if post-redemption public holder concentrations drop below 400. Additionally, the filing supplies detailed PFIC tax guidance, advising U.S. Holders that IRS treatment of redemption proceeds as distributions may strip preferential capital gains rates due to passive asset classification, triggering default PFIC taxation with ordinary income allocation and interest penalties on deferred gains.

What changed: 10-Q quarterly report for Launch One Acquisition Corp. (LPAA) for the period ended March 31, 2026. The Minovia Business Combination Agreement was terminated on January 30, 2026; the company is now seeking alternative targets. A Working Capital Note was executed on March 20, 2026, allowing up to $1,000,000 in loans from the Sponsor (initial $500,000 drawn), with the Sponsor pledging 2,932,500 Class B Ordinary Shares (≈51% of Founder Shares) as collateral under a Credit and Pledge Agreement. Trust account value per share increased from $10.67 at Dec. 31, 2025 to $10.77 at Mar. 31, 2026. Why it matters: The termination of the Minovia deal leaves LPAA without a business combination target less than four months before the July 15, 2026 deadline, raising the risk of liquidation. The new secured working capital loan and pledge of founder shares indicate the Sponsor is financially supporting the search but also creating potential control risks if defaults occur. The trust value per share of $10.77 still provides a modest floor for public shareholders.

What changed: Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed by Launch One Acquisition Corp. (LPAA), a blank check company searching for a business combination. The trust value increased to $245,449,353 ($10.67 per share) from $235,529,521 ($10.24 per share) as of December 31, 2024, due to interest income of $9,919,832. The company's previously announced business combination with Minovia Therapeutics was terminated on January 30, 2026. On March 20, 2026, the sponsor entered into a Working Capital Promissory Note for up to $1,000,000 to fund operations, pledging 2,932,500 Class B shares (51% of founder shares) as collateral. Cash outside the trust fell to $30,146, and the company now has a working capital deficit of $609,961. Management has identified substantial doubt about the company's ability to continue as a going concern. The deadline to complete a business combination is July 15, 2026. Why it matters: The trust value per share is $10.67, below the $10.86 assumed by the user, and the liquidation deadline is July 15, 2026, not January 15, 2027. The termination of the Minovia deal resets the search to zero with less than four months left before forced liquidation. The sponsor's pledge of majority founder shares to secure working capital indicates financial stress and potential control implications if an extension or deal is not achieved. The going concern warning and low cash reserves heighten the risk of no deal and a forced redemption at approximately $10.67 per share, less any expenses.

What changed: An SEC Form 425/8-K Current Report filed by Launch One Acquisition Corp. disclosing the execution of a Working Capital Promissory Note, a Credit Agreement with Keystone Capital Partners, LLC, and a Pledge Agreement securing the underlying lending facility. Per the Registrant’s filings, the Company executed a Working Capital Note with its Sponsor, Launch One Sponsor, LLC, receiving an initial $500,000 tranche on March 20, 2026. The note structures two additional $250,000 tranches that the Sponsor may elect to fund specifically when the Company (A) enters into a letter of intent, memorandum of understanding, or other agreement regarding an initial business combination, or (B) calls a shareholder meeting to extend its deadline to consummate an initial business combination. To finance these advances, Keystone Capital Partners, LLC agreed via a Credit Agreement to lend the Sponsor up to $1,000,000 on a non-recourse basis, secured solely by a Pledge Agreement covering 2,932,500 Class B ordinary shares, representing approximately 51% of the Sponsor’s founder shares. The Sponsor and Cantor Fitzgerald & Co. entered a waiver letter to permit this pledge despite existing Insider Letter transfer restrictions. Crucially, Section 11 of the note includes an irrevocable trust account waiver confirming the Payee holds no claim to the Trust Account or public distributions, preserving the public shareholder trust balance from lender encumbrance. Why it matters: The Registrant’s board of directors and management stated the financing addresses limited year-end cash balances to cover operational expenses and prior business combination efforts. However, the note records a 20% original issue discount, setting the maximum face principal at $1,250,000 against $1,000,000 in actual draws, accruing 8% annual interest with an 18% default adder totaling 26%, and imposing a 10% prepayment penalty. On the issuance date, the Company agreed to withhold up to $25,000 from the initial tranche to reimburse the Sponsor’s funding costs, with additional out-of-pocket reimbursements for refinancing or enforcement capped at $20,000 per occurrence. Because lender recourse is strictly limited to the pledged founder shares and the debt matures upon business combination consummation or liquidation, the Sponsor bears the direct economic risk of failure without jeopardizing public shareholder trust assets. For investors tracking the redemption calendar and extension timeline, the explicit conditioning of the two $250,000 drawdowns on a shareholder extension vote confirms that operational runway remains tied to continued approval, while the steep implicit borrowing costs and expense offsets will further reduce net capital available for transaction pursuit.

What changed: A Form 8-K current report detailing the execution of a Working Capital Promissory Note between Launch One Acquisition Corp. and its sponsor, alongside related credit and pledge agreements with a third-party lender. According to the March 26, 2026 filing, the company entered into a promissory note on March 20, 2026, permitting borrowings up to $1,000,000. The Working Capital Note specifies an initial loan of $500,000 recorded with a $625,000 principal to account for a 20% original issue discount. Two subsequent tranches of $250,000 each may be drawn at the sponsor's sole discretion if the company executes a letter of intent for a business combination or calls a shareholder meeting to extend its deadline; each carries a $312,500 recorded principal. The note stipulates 8% annual interest that escalates to 26% upon default, with maturity triggered by the earlier of business combination completion or liquidation. Concurrently, the Sponsor executed a Credit Agreement with Keystone Capital Partners, LLC to finance these loans, pledging 2,932,500 Class B ordinary shares (representing approximately 51% of founder shares) as non-recourse collateral. The Pledge Agreement grants lenders foreclosure rights solely over the pledged shares. The filing documents a waiver of Insider Letter transfer restrictions to allow the pledge, and formally incorporates a trust waiver whereby the sponsor irreversibly relinquishes any claims against the trust account or public distributions. Why it matters: This transaction directly modifies extension mechanics and sponsor risk profiles. Management cited the company's 'limited cash balance at year end' as the rationale for securing additional working capital, effectively using sponsored debt to fund ongoing operations and avoid forced liquidation votes, thereby keeping the redemption calendar intact. However, by borrowing $1,000,000 from external lenders and encumbering over half of its founder equity, the sponsor has tied its own financial exposure to achieving a deal or successfully extending the deadline. The Credit Agreement creates hard deadlines, defining events of default if the company fails to file an extension proxy or execute a definitive merger agreement by specified dates, which intensifies schedule pressure on management. Cost structures embedded in the note include a $25,000 expense withholding on the initial draw and caps of $20,000 per occurrence for refinancing or enforcement costs, reducing net capital available for targets or general overhead. Standard security parameters noted in the cover page confirm warrants maintain a $11.50 exercise price. Crucially, the trust waiver ensures that neither corporate liabilities nor the sponsor's third-party creditors can access IPO trust proceeds, insulating public redemption values from this financing maneuver while highlighting increased reliance on sponsor-funded bridge capital ahead of a transaction.